**FIRST-QUARTER 2022 RESULTS**

**TOTAL COMPANY**

$11.9B SALES WORLDWIDE

+17.5%¹ ON AN ORGANIC BASIS*

$1.73² ADJUSTED DILUTED EPS

31%³ IN ADJUSTED EPS GROWTH VERSUS PRIOR YEAR

**BUSINESS HIGHLIGHTS**

**INNOVATION IN HEART TECH**

- FDA approval for Aveir™ single-chamber leadless pacemaker that does not require leads to deliver therapy
- Expanded indication for CardioMEMS™ HF System, making this remote monitoring technology accessible to more people with earlier-stage heart failure

**DIABETES CARE GLOBAL LEADERSHIP**

- 26%⁵ SALES GROWTH WITH ~$1B IN FREESTYLE LIBRE® SALES
- FreeStyle Libre is the first and only CGM with expanded reimbursement in Japan to include all people with diabetes who use insulin

**CONTINUE TO FORECAST STRONG FULL-YEAR 2022 EPS GROWTH**

AT LEAST $4.70⁶

In adjusted diluted EPS

**BUSINESS UNIT SALES**

- $3.6B MEDICAL DEVICES
- $5.3B DIAGNOSTICS
- $1.1B ESTABLISHED PHARMACEUTICALS
- $1.9B NUTRITION

**STRENGTH IN DIAGNOSTICS**

- 35%⁶ SALES GROWTH IN DIAGNOSTICS
- $3.3B in COVID-19 testing sales during the first quarter

---


² On a GAAP basis, first-quarter Abbott sales increased 13.8%.

³ First-quarter GAAP diluted EPS was $1.37.

⁴ First-quarter GAAP diluted EPS reflects growth of 37%.

⁵ Abbott projects full-year 2022 diluted earnings per share under GAAP of at least $3.35. Abbott forecasts specified items for the full-year 2022 of $1.35 per share primarily related to intangible amortization, costs related to a voluntary recall, expenses associated with acquisitions, restructuring, and Real Reducio initiation, and other net expenses. Excluding specified items, projected adjusted diluted earnings per share of at least $4.70 remains unchanged for the full-year 2022. On a GAAP basis, first-quarter FreeStyle Libre sales increased 20%.

⁶ FDA approval for Aveir™ single-chamber leadless pacemaker that does not require leads to deliver therapy.

**FORWARD-LOOKING STATEMENTS**

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors,” in an Amendment to Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.